Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Sponsor: Irada Ibrahim-zada
Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Official title: Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2022-02-18
Completion Date
2026-06-09
Last Updated
2026-01-07
Healthy Volunteers
No
Interventions
Anastrozole 1mg
Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
Letrozole 2.5mg
Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
Exemestane 25 mg
Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
Tamoxifen
Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
Locations (1)
University of Kentucky Markey Cancer Center
Lexington, Kentucky, United States